SynthesisJournal of the American Heart Association2025
Cardiopulmonary Exercise Testing for Characterization of Hypertrophic Cardiomyopathy: A Meta-Analysis.
Synthesis in Journal of the American Heart Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy and safety of exercise for hypertrophic cardiomyopathy: a systematic review and meta-analysis.Proceedings (Baylor University. Medical Center) · 2026Pooled it
- Exercise Performance With Aficamten vs Metoprolol in Obstructive Hypertrophic Cardiomyopathy: The MAPLE-HCM Randomized Clinical Trial.JAMA cardiology · 2026Trial
- Hypertrophic cardiomyopathy: state of the art on diagnosis and current therapeutic approach.Cardiovascular ultrasound · 2026Review
- Cardiopulmonary Exercise Testing in the Differential Diagnosis Between Athlete's Heart and Cardiac Pathology: Current Evidence and Diagnostic Challenges.Diagnostics (Basel, Switzerland) · 2026Review
- Heart failure and preserved ejection fraction: pathophysiology, clinical assessment, and management of exercise intolerance.European heart journal · 2026Review
- Role of provocation and exercise imaging for the identification of candidates for cardiac myosin inhibitors.ESC heart failure · 2026Article
- Exercise testing in athletes: an adjunct to diagnose arrhythmogenic cardiomyopathy?Frontiers in cardiovascular medicine · 2026Article
- Integrating Cardiopulmonary Exercise Testing and Stress Echocardiography to Predict Clinical Outcomes in Hypertrophic Cardiomyopathy.Journal of clinical medicine · 2025Article
- Cardiopulmonary Exercise Testing in Hypertrophic Cardiomyopathy: Refining a Proven Tool for Better Risk Prognostication.Journal of the American Heart Association · 2025Article
Corrections and comments
- Commented on by
Authors and funding
10 authors.
Funding
Abstract
backgroundHypertrophic cardiomyopathy (HCM) is associated with substantial risk of adverse cardiac events. Consequently, detailed physiologic assessment and accurate risk stratification in HCM are of high clinical importance. This systematic review and meta-analysis synthesizes current evidence on the utility of cardiopulmonary exercise testing (CPET) for characterization and prognostication of HCM.
methodsPubMed, Embase, Scopus, and Web of Science were systematically searched for eligible studies from database inception to November 2023. The primary outcome of mortality was assessed using meta-analyzed hazard ratios (HRs) and 95% confidence intervals (CIs) from Cox proportional hazard models.
resultsSixty full-length articles focusing on CPETs performed in patients with HCM were included, comprising 12 914 patients. Despite male predominance (66%) and a mean age of 48 years, peak oxygen uptake (pVO
conclusionsCPET is a valuable objective method for multidimensional physiologic assessment and prognostication in HCM. With further standardization, CPET is well suited for more widespread clinical utilization in patients with HCM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.